MX2011011767A - Combinacion antitumoral que comprende ave8062 y sorafenib. - Google Patents

Combinacion antitumoral que comprende ave8062 y sorafenib.

Info

Publication number
MX2011011767A
MX2011011767A MX2011011767A MX2011011767A MX2011011767A MX 2011011767 A MX2011011767 A MX 2011011767A MX 2011011767 A MX2011011767 A MX 2011011767A MX 2011011767 A MX2011011767 A MX 2011011767A MX 2011011767 A MX2011011767 A MX 2011011767A
Authority
MX
Mexico
Prior art keywords
ave8062
sorafenib
combination including
antitumor combination
antitumor
Prior art date
Application number
MX2011011767A
Other languages
English (en)
Inventor
Patricia Vrignaud
Brigitte Demers
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2011011767A publication Critical patent/MX2011011767A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se relaciona con una combinación antitumoral farmacéutica que incluye AVE8062 de fórmula (I) y sorafenib de fórmula (II), en donde ambos agentes antitumorales pueden estar en forma de una base o sal ácida farmacéuticamente aceptable.
MX2011011767A 2009-05-07 2010-05-06 Combinacion antitumoral que comprende ave8062 y sorafenib. MX2011011767A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0902210A FR2945210B1 (fr) 2009-05-07 2009-05-07 Combinaison antitumorale comprenant l'ave8062 et le sorafenib
PCT/FR2010/050874 WO2010128259A1 (fr) 2009-05-07 2010-05-06 Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Publications (1)

Publication Number Publication Date
MX2011011767A true MX2011011767A (es) 2012-02-28

Family

ID=41402172

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011767A MX2011011767A (es) 2009-05-07 2010-05-06 Combinacion antitumoral que comprende ave8062 y sorafenib.

Country Status (27)

Country Link
US (1) US20120108641A1 (es)
EP (1) EP2427185A1 (es)
JP (1) JP2012526090A (es)
KR (1) KR20120023754A (es)
CN (1) CN102438608A (es)
AR (1) AR076848A1 (es)
AU (1) AU2010244254A1 (es)
BR (1) BRPI1014197A2 (es)
CA (1) CA2761146A1 (es)
CL (1) CL2011002782A1 (es)
CO (1) CO6390102A2 (es)
CR (1) CR20110573A (es)
DO (1) DOP2011000335A (es)
EA (1) EA201171366A1 (es)
EC (1) ECSP11011440A (es)
FR (1) FR2945210B1 (es)
IL (1) IL216133A0 (es)
MA (1) MA33346B1 (es)
MX (1) MX2011011767A (es)
NI (1) NI201100191A (es)
PE (1) PE20120323A1 (es)
SG (1) SG175895A1 (es)
TN (1) TN2011000551A1 (es)
TW (1) TW201043225A (es)
UY (1) UY32618A (es)
WO (1) WO2010128259A1 (es)
ZA (1) ZA201108110B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481404A1 (en) * 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
CN103140224A (zh) * 2010-06-18 2013-06-05 赛诺菲 包含奥瑞布林、紫杉烷衍生物和铂衍生物的抗肿瘤组合
FR2968557A1 (fr) * 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
ES2627120T3 (es) 2011-07-08 2017-07-26 Helmholtz-Zentrum für Infektionsforschung GmbH Medicamento para el tratamiento del cáncer de hígado
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
WO2015126903A1 (en) * 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
KR102272993B1 (ko) * 2019-07-09 2021-07-06 충남대학교산학협력단 퀴니딘 유도체를 유효성분으로 함유하는 항암보조제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
ATE328599T1 (de) * 1998-04-03 2006-06-15 Ajinomoto Kk Antitumorale mittel
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
ATE489080T1 (de) * 2001-06-25 2010-12-15 Ajinomoto Kk Antitumorale mittel
ATE529406T1 (de) * 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors

Also Published As

Publication number Publication date
NI201100191A (es) 2012-01-16
DOP2011000335A (es) 2011-12-15
TW201043225A (en) 2010-12-16
CA2761146A1 (fr) 2010-11-11
FR2945210A1 (fr) 2010-11-12
ECSP11011440A (es) 2011-12-30
CR20110573A (es) 2011-12-08
BRPI1014197A2 (pt) 2016-04-26
UY32618A (es) 2010-12-31
FR2945210B1 (fr) 2011-07-01
EA201171366A1 (ru) 2012-05-30
ZA201108110B (en) 2013-01-30
PE20120323A1 (es) 2012-04-17
AR076848A1 (es) 2011-07-13
IL216133A0 (en) 2012-01-31
EP2427185A1 (fr) 2012-03-14
JP2012526090A (ja) 2012-10-25
CO6390102A2 (es) 2012-02-29
CL2011002782A1 (es) 2012-03-30
CN102438608A (zh) 2012-05-02
TN2011000551A1 (fr) 2013-05-24
KR20120023754A (ko) 2012-03-13
US20120108641A1 (en) 2012-05-03
MA33346B1 (fr) 2012-06-01
SG175895A1 (en) 2011-12-29
WO2010128259A1 (fr) 2010-11-11
AU2010244254A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
MX2011011767A (es) Combinacion antitumoral que comprende ave8062 y sorafenib.
PH12014502605A1 (en) Uracyl spirooxetane nucleosides
MX2011008634A (es) Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia.
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
GB201106743D0 (en) Novel compounds
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
IN2014DN10670A (es)
MX2014006004A (es) Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia.
IN2015DN01119A (es)
IN2012DN03182A (es)
TW200942530A (en) Pyridine compounds
MY172422A (en) Pyrazole compound and pharmaceutical use thereof
IN2012DN00765A (es)
TN2013000283A1 (en) Monoterpene derivatives of chalcone or dihydrochalcone and their use as depigmenting agents
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MX2011010359A (es) Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
TN2014000060A1 (en) Benzothiazolone compound
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
IN2014DN10669A (es)
MY163185A (en) 2-methoxy-pyridin-4-yl derivatives
MX2011011716A (es) Derivados de isoquinolina novedosos.
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
MX2011012233A (es) Soluciones de retinoide topicas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal